

CORRECTION

Open Access



# Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity

Yann Cheli<sup>1\*</sup>, Meri K. Tulic<sup>2</sup>, Najla El Hachem<sup>3</sup>, Nicolas Nottet<sup>1</sup>, Arnaud Jacquiel<sup>4</sup>, Maeva Gesson<sup>5</sup>, Thomas Strub<sup>1</sup>, Karine Bille<sup>1</sup>, Alexandra Picard-Gauci<sup>6</sup>, Henri Montaudié<sup>6</sup>, Guillaume E. Beranger<sup>1,2</sup>, Thierry Passeron<sup>2,6</sup>, Pierre Close<sup>3</sup>, Corine Bertolotto<sup>1†</sup> and Robert Ballotti<sup>1†</sup>

**Correction to: Mol Cancer (2021) 20:12**  
<https://doi.org/10.1186/s12943-020-01306-2>

Following the publication of the original paper [1], the authors found out that the [supplementary material](#) is incomplete. Thus, the publication of correction to notify the readers on the error. Updated [supplementary file](#) is provided in this article.

Published online: 27 January 2021

## Reference

1. Cheli Y, Tulic MK, El Hachem N, et al. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity. *Mol Cancer*. 2021;20:12. <https://doi.org/10.1186/s12943-020-01306-2>.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12943-021-01319-5>.

### Additional file 1.

## Author details

The online version contains supplementary material available at <https://doi.org/10.1186/s12943-021-01319-5>.

<sup>1</sup>Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000 Nice, France. <sup>2</sup>Université Nice Côte d'Azur, INSERM, U1065, Team12 Study of the melanocytic differentiation applied to vitiligo and melanoma, 06000 Nice, France.

<sup>3</sup>Laboratory of Cancer Signaling, University of Liège, Liège, Belgium.

<sup>4</sup>Université Nice Côte d'Azur, INSERM, U1065, Team2 Cell death, differentiation and cancer, 06000 Nice, France. <sup>5</sup>Université Nice Côte d'Azur, INSERM, U1065, Imaging platform, 06000 Nice, France. <sup>6</sup>CHU NICE, Département de Dermatologie, 06000 Nice, France.

The original article can be found online at <https://doi.org/10.1186/s12943-020-01306-2>.

\* Correspondence: [Yann.Cheli@univ-cotedazur.fr](mailto:Yann.Cheli@univ-cotedazur.fr)

†Corine Bertolotto and Robert Ballotti contributed equally to this work.

<sup>1</sup>Université Nice Côte d'Azur, INSERM U1065, Team1 Biology and pathologies of melanocytes. Equipe labellisée ARC 2019, 06000 Nice, France  
Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.